FORT COLLINS, CO, December 14, 2018 (PR NEWSWIRE) — Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC:MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that it is appointing Mr. James Sapirstein and Mr. Terry Brostowin to the Board of Directors. In addition, the Company has accepted the resignation of Mr. Juan Francisco Gutierrez from the Board of Directors
How to Make Your Workplace COVID-Secure
28 December, 2021Lorem ipsum dolor sit amet consectetur.
21 December, 2021Which is the Best Hand Sanitiser Dispenser in 2020?
11 August, 2021
Leave a Reply